Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03158831
Other study ID # 2015-5610
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 13, 2016
Est. completion date October 1, 2021

Study information

Verified date November 2021
Source Montefiore Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators are conducting a prospective study to determine the safety and outcomes of placebo-controlled graded drug challenges without prior skin testing in patients with a low-risk history of antibiotic hypersensitivity reaction based on history alone. The investigators hypothesize that the rate of reaction to graded drug challenges without prior skin testing in patients with a low-risk history of drug hypersensitivity reaction based on history alone will not be meaningfully more than the rate of reaction to placebo. The investigators hypothesize that the rate of adverse reactions to drug challenges without prior skin testing will not be meaningfully more than the rate of adverse reactions with prior skin testing as was observed in the investigators' historical clinic cohort.


Description:

Graded drug challenges are the gold standard to exclude an immediate hypersensitivity reaction in patients with a low likelihood of drug allergy and are considered standard of care. Patients who tolerate a graded challenge are deemed to not be allergic to the drug and are not at increased risk for future reactions compared with the general population. Prior studies of graded challenges in appropriately selected patients have demonstrated low reaction rates with symptoms that were mainly mild and subjective in nature. The investigators are conducting a prospective study to determine the safety and outcomes of placebo-controlled graded drug challenges without prior skin testing in patients with a low-risk history of antibiotic hypersensitivity reaction based on history alone. Skin testing requires a separate visit and is, therefore, more time-consuming and costly than performing a graded challenge without skin testing. The investigators believe that they can determine if patients are at low-risk to react to an antibiotic based on a detailed history and, therefore, do not require skin testing prior to a challenge. Given the majority of symptoms to graded drug challenges reported in prior studies were mild and subjective, the investigators hypothesize that the rate of reaction to graded drug challenges without prior skin testing in patients with a low-risk history of drug hypersensitivity reaction based on history alone will not be meaningfully more than the rate of reaction to placebo. The investigators hypothesize that the rate of adverse reactions to drug challenges without prior skin testing will be not meaningfully more than the rate of adverse reactions with prior skin testing as was observed in the investigators' historical clinic cohort. All patients age 7 years or older with a history of a non-life-threatening reaction to an antibiotic are eligible to participate in a placebo-controlled graded drug challenge. The challenge is comprised of placebo followed by 30 minutes of observation, 1/10th of the treatment dose of the antibiotic the patient reported a reaction followed by 30 minutes of observation, and the full dose of the antibiotic followed by 1 hour of observation. All patients will be contacted via telephone within one month of a negative challenge to determine whether they experienced a delayed reaction. All patients will also be contacted via telephone within one year of a negative challenge to determine if they have safely taken the challenge drug.


Recruitment information / eligibility

Status Completed
Enrollment 166
Est. completion date October 1, 2021
Est. primary completion date October 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 7 Years and older
Eligibility Inclusion Criteria: - All patients seven years of age or older who have a low-risk, non-life-threatening history of adverse reaction to an antibiotic. Exclusion Criteria: - Patients under the age of seven. - Pregnant patients. - Patients with a history of a drug reaction that is high-risk and life-threatening including life-threatening angioedema, bronchospasm, or anaphylactic shock or a history of severe non-IgE-mediated reactions including serum sickness, Stevens-Johnson syndrome, toxic epidermal necrolysis, interstitial nephritis, hepatitis, hemolytic anemia, DRESS, skin and/or oral blisters, hypersensitivity vasculitis, pneumonitis, or pulmonary fibrosis. - Patients who have taken antihistamines within 3 days of the drug challenge.

Study Design


Intervention

Drug:
Placebo-Controlled Graded Drug Challenge
All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.

Locations

Country Name City State
United States Montefiore Medical Center Bronx New York

Sponsors (1)

Lead Sponsor Collaborator
Montefiore Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (4)

Iammatteo M, Blumenthal KG, Saff R, Long AA, Banerji A. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):768-74. doi: 10.1016/j.jaip.2014.08.001. Epub 2014 Sep 10. — View Citation

Iammatteo M, Ferastraoaru D, Koransky R, Alvarez-Arango S, Thota N, Akenroye A, Jerschow E. Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):711-717.e2. doi: 10.1016/j.jaip.2016.09.041. Epub 2016 Nov 23. — View Citation

Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273. doi: 10.1016/j.anai.2010.08.002. — View Citation

Macy E, Romano A, Khan D. Practical Management of Antibiotic Hypersensitivity in 2017. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):577-586. doi: 10.1016/j.jaip.2017.02.014. Epub 2017 Mar 29. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of unexpected reaction to graded drug challenges without prior skin testing compared to rate of unexpected reaction to graded drug challenges with prior skin testing. Determine the rate of unexpected reaction to a graded drug challenge without prior skin testing versus the rate of reaction to a graded drug challenge with prior skin testing in the investigators' historical cohort (data on this cohort has already been published: Iammatteo M, Ferastraoaru D, Koransky R, Alvarez-Arango S, Thota N, Akenroye A, Jerschow E. Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):711-717.e2.). It is anticipated the study will take 2 years to enroll 200 patients with subsequent data comparison.
Secondary Rate of unexpected reaction to graded drug challenges versus placebos Determine the rate of unexpected reaction to graded drug challenges without prior skin tests versus the rate of unexpected reaction to placebos in patients with a low-risk history of drug hypersensitivity reaction based on history alone. Patients are monitored for 1 hour after completion of their drug challenge.
Secondary Rate of unexpected delayed reaction to graded drug challenges Determine the rate of unexpected delayed reaction to graded challenges Patients are called within 1 month of their challenge to determine if they had any delayed reactions.
See also
  Status Clinical Trial Phase
Terminated NCT05563610 - Oral Penicillin Challenge and Allergy De-labeling in Children Phase 4
Completed NCT05020327 - Inpatient Penicillin Allergy Delabeling Study Phase 4
Completed NCT04441021 - Feasibility Assessment of Risk Stratification and Oral Challenge in Hospitalized Children at Low Risk for Antibiotic Allergy
Not yet recruiting NCT05956080 - Penicillin Allergy Delabeling Among Surgical Patients N/A
Recruiting NCT03757052 - Amoxicillin Challenge for Penicillin Allergy Diagnosis N/A
Completed NCT03702270 - The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal N/A
Recruiting NCT05464615 - Geisinger Antibiotic Allergy Pilot Program: Assess and Address Early Phase 1
Completed NCT03702283 - Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal in ICU Setting N/A
Not yet recruiting NCT03499457 - Penicillin Allergy in Shfayim Clinic N/A
Completed NCT01667055 - The Diagnosis of Beta-lactam Hypersensitivity in Thailand
Withdrawn NCT00589251 - Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique N/A
Completed NCT04620746 - Penicillin Allergy Testing in STD Clinics Phase 4
Completed NCT05090527 - Penicillin Allergy Delabeling Project N/A
Completed NCT03033394 - Beta-lactam Pharmacokinetics in Secondary Care
Completed NCT02036840 - Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients N/A
Terminated NCT00363688 - Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin Phase 4
Recruiting NCT06303128 - Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge Phase 3
Completed NCT03942731 - Penicillin Allergy Testing and Resensitization Rate
Completed NCT05010304 - Penicillin De-labeling in the Pediatric Primary Care Setting Phase 4
Completed NCT03404804 - Oral Challenge in the Pediatric ED Phase 4